LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference

Rhea-AI Summary

LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company, announced that its CEO, Stephen Hurly, will present at the 2023 SVB Securities Global Biopharma Conference.

The presentation is scheduled for February 16, 2023, from 1:00 p.m. to 1:30 p.m. EST. A webcast will be available on the company's investor relations page and archived for 90 days post-event.

LAVA focuses on developing its proprietary Gammabody™ platform to create bispecific gamma-delta T cell engagers for cancer treatment, with notable pipeline candidates including LAVA-051 and LAVA-1207.

UTRECHT, The Netherlands and PHILADELPHIA, Feb. 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will present at the 2023 SVB Securities Global Biopharma Conference.

Presentation Details
Format: Presentation
Date: Thursday, February 16, 2023
Time: 1:00 p.m.-1:30 p.m. EST

A webcast of the presentation can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at: https://ir.lavatherapeutics.com/news-events/events. A replay will be archived for 90 days following the presentation date.

About LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company utilizing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. LAVA-051, the Company’s lead candidate for the treatment of multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia, is enrolling patients in a Phase 1/2a clinical study (NCT04887259). A Phase 1/2a clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is also enrolling (NCT05369000). For more information, please visit www.lavatherapeutics.com, and follow us on LinkedIn, Twitter and YouTube.

CONTACTS
Investor Relations
ir@lavatherapeutics.com

Argot Partners (IR/Media)
212-600-1902
lava@argotpartners.com

FAQ

What is LAVA Therapeutics presenting at the 2023 SVB Securities Global Biopharma Conference?

LAVA Therapeutics will present developments regarding its Gammabody™ platform and bispecific gamma-delta T cell engagers.

When is LAVA Therapeutics' presentation scheduled at the conference?

The presentation is scheduled for February 16, 2023, from 1:00 p.m. to 1:30 p.m. EST.

Where can I watch the LAVA Therapeutics conference presentation?

You can watch the presentation on LAVA Therapeutics' investor relations website under the 'Events' tab.

What is the primary focus of LAVA Therapeutics?

LAVA Therapeutics focuses on developing bispecific gamma-delta T cell engagers for treating cancer.

What are the lead candidates in LAVA Therapeutics' pipeline?

LAVA's lead candidates include LAVA-051 for multiple myeloma and LAVA-1207 for metastatic castration-resistant prostate cancer.